Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
28,000
Employees28,000
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
28,000
Employees28,000

AMGN Key Statistics

Market cap
184.67B
Market cap184.67B
Price-Earnings ratio
26.46
Price-Earnings ratio26.46
Dividend yield
2.78%
Dividend yield2.78%
Average volume
3.06M
Average volume3.06M
High today
$347.26
High today$347.26
Low today
$338.75
Low today$338.75
Open price
$341.63
Open price$341.63
Volume
3.15M
Volume3.15M
52 Week high
$353.25
52 Week high$353.25
52 Week low
$261.43
52 Week low$261.43

Stock Snapshot

With a market cap of 184.67B, Amgen(AMGN) trades at $341.50. The stock has a price-to-earnings ratio of 26.46 and currently yields dividends of 2.8%.

On 2026-01-29, Amgen(AMGN) stock moved within a range of $338.75 to $347.26. With shares now at $341.50, the stock is trading +0.8% above its intraday low and -1.7% below the session's peak.

Trading activity shows a volume of 3.15M, compared to an average daily volume of 3.06M.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $353.25 and a low of $261.43.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $353.25 and a low of $261.43.

AMGN News

Nasdaq 9h
Upcoming Dividend Run For AMGN?

This morning a "Potential Dividend Run Alert" went out for Amgen Inc (NASD: AMGN), at our DividendChannel.com Dividend Alerts service (a free email alerts featu...

Upcoming Dividend Run For AMGN?
TipRanks 10h
Amgen price target raised to $400 from $380 at Oppenheimer

Oppenheimer raised the firm’s price target on Amgen (AMGN) to $400 from $380 and keeps an Outperform rating on the shares ahead of quarterly results. The firm e...

Nasdaq 22h
Missed Out on Eli Lilly? This GLP-1 Stock Could Be a Bargain Buy.

Key Points Eli Lilly's stock trades at more than 30 times forward earnings, which is a steep price to pay right now. Amgen is a much cheaper option by compari...

Missed Out on Eli Lilly? This GLP-1 Stock Could Be a Bargain Buy.

Analyst ratings

48%

of 33 ratings
Buy
45.5%
Hold
48.5%
Sell
6.1%

More AMGN News

Simply Wall St 22h
Amgen Faces 340B Legal Challenge As Stock Trades Near Analyst Views

Sagebrush Health Services has filed a lawsuit against Amgen alleging improper actions related to the 340B Drug Pricing Program. The complaint focuses on claims...

Amgen Faces 340B Legal Challenge As Stock Trades Near Analyst Views
Simply Wall St 2d
Is It Time To Reassess Amgen After Strong Multi Year Share Price Gains

If you are wondering whether Amgen's current share price lines up with its underlying value, you are not alone. This article is built to walk you through that q...

Is It Time To Reassess Amgen After Strong Multi Year Share Price Gains
TipRanks 2d
Amgen Advances Teprotumumab Program With Completed Phase 1 Study in Healthy Chinese Volunteers

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools f...

Simply Wall St 4d
Will 340B Lawsuit Over Drug Discounts Shift Amgen's Access Strategy And Investment Narrative?

Sagebrush Health Services has filed a lawsuit in California Superior Court against Amgen Inc., alleging unlawful termination of 340B drug discounts and improper...

Will 340B Lawsuit Over Drug Discounts Shift Amgen's Access Strategy And Investment Narrative?
Simply Wall St 6d
Assessing Amgen Valuation After The New Sagebrush 340B Lawsuit

Advertisement Why the Sagebrush lawsuit matters for Amgen stock The new lawsuit from Sagebrush Health Services puts Amgen (AMGN) and its role in the 340B Drug...

Assessing Amgen Valuation After The New Sagebrush 340B Lawsuit
Seeking Alpha 6d
Amgen snaps after six straight sessions of gains

Amgen (NASDAQ:AMGN) snapped six consecutive sessions of gains, as the company’s shares closed 0.66% lower at $344.78 on Friday. In the preceding six sessions,...

Amgen snaps after six straight sessions of gains

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.